Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07473713
PHASE1

Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia

Sponsor: Tufts Medical Center

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are: * How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion. * Describe the safety of veverimer based on changes in serum bicarbonate and potassium. * Assess the changes in bone resorption. * Assess the changes in bone formation. * Explore the effect of veverimer on physical performance. Participants will: * Take veverimer or placebo every day or every other day for 8 weeks * Visit the clinic a total of 8 times (including screening) for checkups and testing * Keep a medication diary tracking each day they take the study drug

Official title: Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia: a Dose-finding Randomized Controlled Trial

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-04-15

Completion Date

2028-05-01

Last Updated

2026-04-06

Healthy Volunteers

No

Conditions

Interventions

DRUG

veverimer daily

8 weeks of taking 9 grams of veverimer (a powder mixed into water) daily

DRUG

veverimer every other day

8 weeks of taking 9 grams of veverimer (a powder mixed into water) every other day

OTHER

Placebo

8 weeks taking 9 grams microcrystalline cellulose (powdered mixed into water) daily or every other day

Locations (1)

Tufts Medical Center

Boston, Massachusetts, United States